Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Operating Expenses (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Operating Expenses for 9 consecutive years, with $6.9 million as the latest value for Q4 2024.

  • On a quarterly basis, Operating Expenses fell 15.4% to $6.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $31.5 million, a 16.78% decrease, with the full-year FY2024 number at $31.5 million, down 16.78% from a year prior.
  • Operating Expenses was $6.9 million for Q4 2024 at SELLAS Life Sciences, down from $7.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $17.7 million in Q1 2022 to a low of $4.1 million in Q1 2020.
  • A 5-year average of $8.2 million and a median of $7.8 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 123.22% in 2022, then tumbled 36.39% in 2023.
  • SELLAS Life Sciences' Operating Expenses stood at $6.1 million in 2020, then soared by 91.76% to $11.6 million in 2021, then decreased by 18.7% to $9.4 million in 2022, then fell by 13.43% to $8.2 million in 2023, then fell by 15.4% to $6.9 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Operating Expenses are $6.9 million (Q4 2024), $7.3 million (Q3 2024), and $7.6 million (Q2 2024).